A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities

NCT05869903 · Active, not recruiting

Last updated 2026-05-28

This clinical trial is testing the safety and effectiveness of the medication Orforglipron (LY3502970) in adults who have obesity or are overweight and have weight-related health issues.

Status Active, not recruiting Ongoing, but no longer enrolling new participants.

Phase Phase 3 Confirms effectiveness in a large group before approval.

Type Interventional (clinical trial)

Design Randomized, double-blind treatment study

Participants 3,127 people

Who can join Ages 18+ · all sexes

Timeline Started 2023-06 · est. completion 2027-10

Where 138 sites · Brazil, China, India, Japan, Puerto Rico, Slovakia, South Korea, Spain, Taiwan, United States

What this study is testing ClinicalTrials.gov NCT05869903 ↗

Description as written by the study sponsor.

This study will investigate the efficacy and safety of once daily oral orforglipron in adult participants with obesity or overweight with weight-related comorbidities. The study has two phases: a main phase and an extension phase. The main phase of the study lasted 72 weeks. Participants with prediabetes will continue in the extension for another 2 years.

Treatments tested

Orforglipron also known as LY3502970 Drug

Administered orally.
Placebo Drug

Administered orally.

Main thing measured	Mean Percent Change from Baseline in Body Weight
Sponsor	Eli Lilly and Company
Conditions studied	Obesity, Overweight, Overweight or Obesity
GLP-1 drugs	orforglipron

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT05869903 ↗